INTERACTIONS between antibiotics and negatively charged substances have already been described (Jacobs et al., 1973; Jacques, 1979) . In particular adriamycin, an anthracycline antibiotic widely used as an anticancer agent, has been shown to form ionic associations with negatively charged phospholipids, and to give rise to complexes with sulphated mucopolysaccharides such as heparin and chondroitinsulphate (Menozzi & Arcamone, 1978) . When adriamycin and heparin are administered simultaneously, as occurs in some cancer patients (Hilgard & Thornes, 1976) , a temporary reduction of the anticoagulant activity of lieparin may ensue (Cofrancesco et al., 1980) . Daunomycin (DNM), an aminoglycosidic antibiotic the structure of which is very similar to that of adriamycin, is widely used in the treatment of acute leukaemias (Jacquillat et al., 1979) and is therefore very often associated with heparin in order to prevent disseminated intravascular coagulation and subsequent fatal haemorrhage (Nomura et al., 1974; Drapkin et al., 1978) .
In this paper, we evaluate the possible interactions between DNM and heparin in acute leukaemia patients treated with a standard clinical protocol.
Eighteen cycles of DNM treatment (in 15 patients) were studied; in each second cycle DNM was associated with heparin treatment. Complete evaluation of DNM Acceptedl 1 Auigust 1980 disappearance curves was only possible in 15 cycles (9 cycles in 9 patients receiving DNM, Group A, and 6 cycles in 5 patients receiving DNM + heparin, Group B) in view of difficulties in collecting serial blood samples in 3 cycles (all in Group B). (Bennett et al., 1976 I Abnormal: alkaline phosphatase, SGOT-SGPT, y-GT, plasma protein patterin.
after DNM administration. In Group B patients, blood was collected before the start of heparin treatment too, and at various intervals during the joint drug treatment for measurement of thrombin time.
Venous blood was drawn into test tubes containing 1 part of 01 26M trisodium citrate to 9 parts of blood. The samples were immediately centrifuged for 20 min at 4000 rev/min and supernatant cell-free plasma was stored at -20°C until use. Total plasma DNM-associated fluorescence was measured according to Finkel et al. (1969) , thrombin time was measured according to Vermylen & Verstraete (1960) .
The time course of DNM plasma concentrations for each patient was tested for linear regression before being fitted to the triexponential equation: ln C=ln (A e-at +B e-fIt+C e-vt) The correlation coefficients were statistically significant, thus confirming a good fit to the model adopted.
Pharmacokinetic parameters considered were: apparent half lives (t1/2); area under the curve (AUCS), theoretical area under the curve (AUCT); the apparent volume of distribution (Vd) and plasma clearance (Clp) (Wagner, 1971 ).
Fourteen of the 15 cycles of DNM treatment monitored fitted a 3 compartment open-model pharmacokinetic analysis. Patient No. 12 with L2 leukaemia was excluded, as his DNM plasma levels were at a plateau and more appropriately fitted a one compartment model. Fig. 1 shows plots of the theoretical plasma DNM decay for Groups A and B. In Group A, the curves of patients 8 and 9, who had L2 leukaemia, are marked with a broken line in the graph, and have been considered separately in further evaluation.
The kinetic profile of the 2 groups of curves was superimposable, the results being somewhat more variable in Group A than in Group B, as was indicated by the generally higher standard deviation (s.d.) and the wider range of kinetic parameters of this group (Table II) . Plasma disappearance of DNM in Patients 4 and 6 followed similar kinetics both in the presence and absence of heparin. In Group B patients, an optimal degree of anticoagulation was achieved immediately (5 min) and at various intervals (10, 15, 30 and 60 min) after administration of DNM (data not shown).
This study shows that the concomitant administration of heparin does not modify DNM disappearance curves in a group of acute leukaemia patients. Since the results were obtained with a method which measures total fluorescence linked to DNM and to its metabolites, we cannot rule out the possibility that the relative proportions of the intact drug and its metabolites would be changed in the presence of heparin. The DNM plasma decay curves could be well fitted to a triphasic pattern, as Huffman et al. (1972) reported for total DNM fluorescence in a population of acute leukaemia patients.
The DNM plasma levels we found were lower than those obtained bv Huffman et al. (1972) after administration of double our dose, but were similar to those reported by Alberts et al. (1971) and heparin anticoagulation was transiently recluced by adriamycin both in humans (Cofrancesco et al., 1980) and in mice (Poggi et al., submitted) . However, in mice, even this interaction did not cause marked interference with either the plasma disappearance and tissue distribution or the antitumoral activity of the drug.
